|
 iBio, Inc. (NYSE MKT: IBIO)
IBIO (IBIO, Inc.) reported today that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a contract to the Company's research and development collaborator, the Fraunhofer USA Center for Molecular Biotechnology, for a new generation anthrax vaccine to be developed with the iBioLaunch? Platform under a research license from IBIO (IBIO, Inc.). The first year of funding will be $1.76 million with a total contract amount of up to $9.9 million, depending on the exercise of contract options. 
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. iBio, Inc. (NYSE MKT: IBIO) develops and offers product applications of its iBioLaunch? and iBioModulator? platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Further information is available at: www.ibioinc.com. In my opinion this is a stock to watch! (Read Full Disclaimer at http://crweselect.com/disclaimer)
Related Articles -
iBioLaunch, iBioModulator, NYSE MKT: IBIO,
| 
